RE:Sutro BiopharmaGood find risetothetop excellent!
The Pharmaceutical Partner has been working with EnWave since 2012 to evaluate REV™ technology as a viable replacement for lyophilization in the pharmaceutical industry.
In 2012, Sutro and Celgene entered into a collaboration to design and develop ADCs and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody.